Baclofen |
Herman et al. 199271 USA RCT PEDro=8 |
N:10 Type of pain: Mixed group |
Treatment: Baclofen and placebo were randomly administered into L1-2 inter-space of each of 7 SCI patients. In the non-RCT group only 2 subjects were enrolled in the study. Pain Scale: Not stated |
Intrathecal baclofen significantly suppressed neurogenic (burning quality) pain among 6 of the 7 RCT subjects (p<0.001).
Pinch inducted pain was not affected by either placebo or Baclofen.
|
Loubser and Akman 199676 USA Pre-Post D&B=13 |
N:16 Type of pain: Mixed group |
Treatment: Baclofen infusion pump was implanted into SCI patients. Pain Scale: VAS |
12/16 patients described chronic pain prior to procedure.
No significant differences were noted between VAS at the 6 and 12-month assessments following pump implantation.
For those with neuropathic pain symptoms, ANOVA revealed a non-significant effect of intrathecal baclofen on pain at both 6 and 12 months. (p=0.26).
In 5 of 6 patients with musculoskeletal pain symptoms, pain severity decreased in conjunction with control of spasticity. Musculoskeletal pain responded to baclofen infusion, while neuropathic pain did not.
|
Botulinum Toxin |
Marciniak et al. 200877 USA Case series D&B=12 |
N:28 Type of pain: Mixed group |
Treatment: Botulinum toxin (BTX) type A injection for focal spasticity control. Pain Scale: Not stated |
-
Improvement was seen post-injection in:
The effectiveness of the BTX injections was not influenced by early use of BTX injections (less than a year after onset of symptoms) vs. late use.
Improvement in those with upper arm compared to lower arm injections was similar. Also, level of completeness of the SCI did not effect improvement.
|